Bain Capital Investor Portal Please log in to access your account information. If you have any questions regarding your account, please contact [email protected].
SOUTH SAN FRANCISCO, CA, December 19, 2018 - Annexon Biosciences, a clinical stage biopharmaceutical company focused on the development of novel therapeutics through inhibition of the classical complement pathway, today announced that it has closed a $75 million Series C financing. The financing was led by new investor Bain Capital Life Sciences, with participation by Surveyor Capital (a Citadel...
SAN DIEGO, November 29, 2018 – ViaCyte, Inc., a privately-held clinical stage regenerative medicine company, today announced an $80 million Series D financing led by Bain Capital Life Sciences and joined by TPG and RA Capital Management, as well as existing investor, Sanderling Ventures, and several individual supporters of the Company. Proceeds from the financing will be used to further...
BOSTON and NEW YORK, October 23, 2018 – Bain Capital, LP and Pfizer Inc. (NYSE: PFE) today announced the creation of Cerevel Therapeutics, LLC (“Cerevel”), a new biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). Pfizer is contributing a portfolio of pre-commercial neuroscience assets to Cerevel, which include three...
LOWELL, MA, May 2, 2018 – Rapid Micro Biosystems, the leading provider of automated, growth-based, rapid microbial detection technology for the healthcare product manufacturing sector, announced that it has secured $60 million in equity financing led by new investors Bain Capital Life Sciences and Xeraya Capital. The new funding round also includes a commitment from another new investor, Asahi...
EVANSTON, ILLINOIS, December 18, 2017 – Aptinyx Inc., a clinical-stage biopharmaceutical company developing transformative therapies for challenging neurologic disorders, today is announcing the completion of a $70 million Series B financing to fund advancement of its expanding clinical-stage pipeline. The financing was led by Bain Capital Life Sciences. Additional new investors include Adage...
JENA, GERMANY, October 13, 2017 - InflaRx, the biopharmaceutical company developing new therapeutics in the terminal complement space, announced today a $ 55M Series D financing and investment round. The round was co-led by Bain Capital Life Sciences LP, Cormorant Asset Management LLC and RA Capital Management LLC and complemented by certain investment funds managed by a leading US investment...
NEW YORK, September 25, 2017 - SpringWorks Therapeutics, a mission-driven medicines company dedicated to developing innovative potential new treatments for underserved patient communities, announced its launch today with a completed $103 million Series A financing funded by Bain Capital Life Sciences, Bain Capital Double Impact, OrbiMed, Pfizer (NYSE:PFE) and LifeArc (formerly known as...
WOBURN, MA, September 8, 2017 – Replimune Group Inc., a biotechnology company focused on developing next generation oncolytic immunotherapies, announced today the completion of a $55 million Series B financing. The proceeds of the financing will primarily be used to generate human proof of concept data for its lead product, RP1, in multiple tumor types. The financing will also allow the Company...
CAMBRIDGE, MA, March 30, 2017 - Solid Biosciences announced today that it has completed the initial closing of its $50 Million Series C financing, which the company will use to progress its portfolio of programs targeted at Duchenne muscular dystrophy (DMD). The round was led by RA Capital Management and Bain Capital Life Sciences, together with funds from RTW Investments, Foresite Capital,...
CAMBRIDGE, MA, March 30, 2017 - Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) (the “Company”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that it has signed a stock purchase agreement with a syndicate of current and new investors, led by Bain Capital Life Sciences, for the sale of redeemable convertible preferred stock...
Kim is helping others — and @YearUp itself — an exemplar of Year Up’s “lift while you climb” model. #BainCapitalCP https://t.co/a9NlBXHUxM
"Muggia’s involvement with City Year has deeply impacted her life and she wants everyone to be fired up about… https://t.co/ouyVMU3cBC
Personalizing Treatment: The Latest in Breast Cancer Research. #BainCapitalCP https://t.co/1riwodh2sc
Three Reasons I Decided To Serve Another @CityYear. https://t.co/WteKdt90xH #BainCapitalCP https://t.co/YzDBGavkDC
Make a difference to your local community with @communityserv. https://t.co/6l4lTM9Fsv
Learn how @RosiesPlace brings services to the community. #BainCapitalCP https://t.co/TUpdFt7k8F
Pi Day: Infinite Ways to Celebrate the Magic of Circles. https://t.co/vootXlUHzZ. #BainCapitalCP
In 2018, Bain Capital built new partnerships and deepened existing relationships with nonprofits around the world.… https://t.co/1pKi8u4lcQ
Cancer survivor celebrates 10 years in remission by sharing advice with others. https://t.co/aLDGaddLLL #BainCapitalCP
Learn how @YearUp is making an impact on workforce development. https://t.co/pXqCZ4zZEQ